dd-cfDNA Assessment for Liver Transplant Rejection Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting acute rejection in liver transplant recipients are inadequate, leading to arbitrary immunosuppressive adjustments that can trigger rejection or require higher dosing, lacking specific biomarkers for immune activation and graft dysfunction.
Innovation Solution
Utilizing donor-derived cell-free DNA (dd-cfDNA) levels in recipients, analyzed through sequencing and algorithms, to distinguish between acute rejection (AR) and acute dysfunction non-rejection (ADNR) by comparing dd-cfDNA levels to predetermined thresholds, enabling minimally invasive assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressant regimens are prescribed to prevent acute rejection, then graft survival is improved, but complications such as nephrotoxicity increase
Solution Approach 1:
The patent applies parameter changes by monitoring dd-cfDNA levels to dynamically adjust immunosuppressant dosing parameters. Instead of fixed dosing, the regimen is tailored based on measured dd-cfDNA concentrations, allowing optimization of the balance between preventing rejection and minimizing toxicity. This enables individualized dosing that adapts to each patient's actual immune activation state.
Solution Approach 2:
The patent implements feedback control through continuous monitoring of dd-cfDNA levels in recipient plasma. This biomarker serves as a feedback signal that indicates immune activation status, allowing clinicians to adjust immunosuppressant regimens in real-time. The feedback loop enables proactive adjustment before actual rejection occurs, while avoiding unnecessary immunosuppression that leads to complications.
2Object-affected harmful factors
If immunosuppressive minimization protocols are implemented to prevent complications, then nephrotoxicity is reduced, but arbitrary trial and error adjustments may trigger rejection
Solution Approach 1:
The patent applies preliminary action by detecting elevated dd-cfDNA levels before clinical rejection manifests. This early warning system allows clinicians to intervene with immunosuppressant adjustment before the rejection process becomes irreversible. The dd-cfDNA biomarker provides advance notice of immune activation, enabling preventive rather than reactive management.
Solution Approach 2:
The patent implements feedback control through continuous monitoring of dd-cfDNA levels in recipient plasma. This biomarker serves as a feedback signal that indicates immune activation status, allowing clinicians to adjust immunosuppressant regimens in real-time. The feedback loop enables proactive adjustment before actual rejection occurs, while avoiding unnecessary immunosuppression that leads to complications.
3Loss of information
If liver function tests are performed to assess graft function, then monitoring capability is provided, but the tests are suboptimal for detecting immune activation
Solution Approach 1:
The patent applies the extraction principle by isolating and measuring specifically the donor-derived fraction of cell-free DNA in the recipient's plasma. This separates the relevant diagnostic information (dd-cfDNA from donor liver cells) from the background of recipient DNA and other plasma components. The extraction of this specific biomarker provides precise measurement of graft-derived material, enabling accurate detection of immune activation and graft dysfunction independent of standard liver function tests.
Data Source
Figure 1
Figure 2A~2B
Figure 2C
AI summary
Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in liver transplant recipients involving an assessment of donor-derived cell-free nucleic acids (dd-cfNA) such as donor-derived cell-free DNA (dd-cfDNA).